Suppr超能文献

血管紧张素II诱导易卒中型自发性高血压大鼠的心肌细胞肥大和心脏纤维化。

Angiotensin II-induced cardiomyocyte hypertrophy and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.

作者信息

Ikeda Y, Nakamura T, Takano H, Kimura H, Obata J E, Takeda S, Hata A, Shido K, Mochizuki S, Yoshida Y

机构信息

Department of Internal Medicine, Yamanashi Medical University, Japan.

出版信息

J Lab Clin Med. 2000 Apr;135(4):353-9. doi: 10.1067/mlc.2000.105617.

Abstract

Angiotensin-converting enzyme inhibitors (ACEIs) cause regression of hypertensive left ventricular hypertrophy (LVH) by reducing angiotensin II, increasing bradykinin, or both. The mechanisms of these cardioprotective effects remain controversial. The aims of this study were to determine whether the cardioprotective effects of ACEIs are mediated by reducing angiotensin II and whether ACEIs ameliorate the morphologic, physiologic, and biochemical changes in the hearts of stroke-prone spontaneously hypertensive rats (SHRSPs). Male SHRSPs were treated with hydralazine, captopril, or candesartan, an angiotensin II type 1 receptor (AT1R) antagonist, from age 12 to 24 weeks. We measured systolic blood pressure (SBP), left ventricular weight (LVW), left ventricular (LV) myocyte cross-sectional area (myocyte size), LV Interstitial collagen volume fraction (ICVF), perivascular collagen area/luminal area ratio (PVCA/LA), the medial area to luminal area ratio (MA/LA), the relative amount of V3 myosin heavy chain (MHCV3), and coronary reserve maximum (coronary flow max/ventricular weight (CFmax/VW)). These parameters were compared with those of untreated SHRSPs and Wistar-Kyoto rats (WKYs). SHRSPs exhibited decreased coronary reserve and LVH with an increase in myocyte size, PVCA/LA, MA/LA, and MHCV3 at 12 weeks of age. In addition to these changes, 24-week-old SHRSPs showed an increase in ICVF. The LVW, coronary reserve, myocyte size, PVCA/LA, ICVF, and MHCV3 of SHRSPs treated with captopril or candesartan all approached control values. In contrast, hydralazine decreased only ICVF. These results suggest that ACEIs regress LVH and normalize coronary reserve by modulating the effects of angiotensin II via AT1R on the induction of cardiomyocyte hypertrophy, perivascular fibrosis, and medial thickening of intramyocardial coronary arteries in SHRSPs. We concluded that these effects, in addition to the reduction of SBP, are important in causing the regression of LVH.

摘要

血管紧张素转换酶抑制剂(ACEIs)通过减少血管紧张素II、增加缓激肽或两者兼而有之,使高血压左心室肥厚(LVH)消退。这些心脏保护作用的机制仍存在争议。本研究的目的是确定ACEIs的心脏保护作用是否通过减少血管紧张素II介导,以及ACEIs是否能改善易患中风的自发性高血压大鼠(SHRSPs)心脏的形态、生理和生化变化。雄性SHRSPs在12至24周龄时用肼屈嗪、卡托普利或坎地沙坦(一种血管紧张素II 1型受体(AT1R)拮抗剂)进行治疗。我们测量了收缩压(SBP)、左心室重量(LVW)、左心室(LV)心肌细胞横截面积(心肌细胞大小)、LV间质胶原容积分数(ICVF)、血管周围胶原面积/管腔面积比(PVCA/LA)、中膜面积与管腔面积比(MA/LA)、V3肌球蛋白重链(MHCV3)的相对量以及冠状动脉储备最大值(冠状动脉血流最大值/心室重量(CFmax/VW))。将这些参数与未治疗的SHRSPs和Wistar-Kyoto大鼠(WKYs)的参数进行比较。SHRSPs在12周龄时表现出冠状动脉储备降低和LVH,同时心肌细胞大小、PVCA/LA、MA/LA和MHCV3增加。除了这些变化外,24周龄的SHRSPs还表现出ICVF增加。用卡托普利或坎地沙坦治疗的SHRSPs的LVW、冠状动脉储备、心肌细胞大小、PVCA/LA、ICVF和MHCV3均接近对照值。相比之下,肼屈嗪仅降低了ICVF。这些结果表明,ACEIs通过调节血管紧张素II通过AT1R对SHRSPs中心肌细胞肥大、血管周围纤维化和心肌内冠状动脉中膜增厚的诱导作用,使LVH消退并使冠状动脉储备正常化。我们得出结论,这些作用除了降低SBP外,对导致LVH消退也很重要。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验